Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Melissa O'Neil, MRT(T)

Advertisement

Articles by Melissa O'Neil, MRT(T)

Melissa O'Neil, MRT(T), advanced practice radiation therapist, leader, Rapid Response Clinic, London Regional Cancer Program, Ontario, Canada,

O'Neil on the Feasibility of Diagnostic CT-Enabled Planning For Patients Receiving Palliative Radiation Therapy

ByMelissa O'Neil, MRT(T)
October 4th 2023

Melissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management

    2

    Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

    3

    Carotuximab Plus Apalutamide Improves PFS in mCRPC

    4

    Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma

    5

    Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us